Viewing Study NCT05442060

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:05 AM
Ignite Modification Date: 2026-06-14 @ 7:19 AM
Study NCT ID: NCT05442060
Status: RECRUITING
Last Update Posted: 2025-08-03
First Post: 2022-06-28
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: OBI Pharma, Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None OBI-833/OBI-821 View
None Erlotinib View
None EGFR-Mutated View
None Globo H View
None Globo H positive View
None Locally advanced non-small cell lung cancer View
None Metastatic non-small cell lung cancer View
None NSCLC View